These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29969596)

  • 1. Comparison of Dual β-Lactam therapy to penicillin-aminoglycoside combination in treatment of Enterococcus faecalis infective endocarditis.
    El Rafei A; DeSimone DC; Narichania AD; Sohail MR; Vikram HR; Li Z; Steckelberg JM; Wilson WR; Baddour LM
    J Infect; 2018 Nov; 77(5):398-404. PubMed ID: 29969596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone.
    Pericas JM; Cervera C; del Rio A; Moreno A; Garcia de la Maria C; Almela M; Falces C; Ninot S; Castañeda X; Armero Y; Soy D; Gatell JM; Marco F; Mestres CA; Miro JM;
    Clin Microbiol Infect; 2014 Dec; 20(12):O1075-83. PubMed ID: 25040215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of penicillin-gentamicin and dual beta-lactam therapies in Enterococcus faecalis infective endocarditis.
    Freeman L; Milkovits A; McDaniel L; Everson N
    Int J Antimicrob Agents; 2022 Mar; 59(3):106522. PubMed ID: 35038556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis.
    Fernández-Hidalgo N; Almirante B; Gavaldà J; Gurgui M; Peña C; de Alarcón A; Ruiz J; Vilacosta I; Montejo M; Vallejo N; López-Medrano F; Plata A; López J; Hidalgo-Tenorio C; Gálvez J; Sáez C; Lomas JM; Falcone M; de la Torre J; Martínez-Lacasa X; Pahissa A
    Clin Infect Dis; 2013 May; 56(9):1261-8. PubMed ID: 23392394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.
    Gil-Navarro MV; Lopez-Cortes LE; Luque-Marquez R; Galvez-Acebal J; de Alarcon-Gonzalez A
    J Clin Pharm Ther; 2018 Apr; 43(2):220-223. PubMed ID: 29030859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four weeks versus six weeks of ampicillin plus ceftriaxone in Enterococcus faecalis native valve endocarditis: A prospective cohort study.
    Ramos-Martínez A; Pericàs JM; Fernández-Cruz A; Muñoz P; Valerio M; Kestler M; Montejo M; Fariñas MC; Sousa D; Domínguez F; Ojeda-Burgos G; Plata A; Vidal L; Miró JM;
    PLoS One; 2020; 15(8):e0237011. PubMed ID: 32745091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse.
    Danneels P; Hamel JF; Picard L; Rezig S; Martinet P; Lorleac'h A; Talarmin JP; Buzelé R; Guimard T; Le Moal G; Brochard-Libois J; Beaudron A; Letheulle J; Codde C; Chenouard R; Boutoille D; Lemaignen A; Bernard L; Cattoir V; Dubée V;
    Clin Infect Dis; 2023 Jan; 76(2):281-290. PubMed ID: 36124844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Success of ampicillin plus ceftriaxone rescue therapy for a relapse of Enterococcus faecalis native-valve endocarditis and in vitro data on double beta-lactam activity.
    Miro JM; Cervera C; Garcia-de-la-Maria C; Del Rio A; Armero Y; Mestres CA; Grau JM; Marco F; Moreno A
    Scand J Infect Dis; 2008; 40(11-12):968-72. PubMed ID: 18767002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides.
    Gavaldá J; Onrubia PL; Gómez MT; Gomis X; Ramírez JL; Len O; Rodríguez D; Crespo M; Ruíz I; Pahissa A
    J Antimicrob Chemother; 2003 Sep; 52(3):514-7. PubMed ID: 12917251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Infective endocarditis due to high level aminoglycoside resistant Enterococcus faecalis and methicillin resistant coagulase-negative staphylococci presenting with rheumatic manifestations].
    Pişkin N; Akduman D; Aydemir H; Celebi G; Oztoprak N; Aktaş E
    Mikrobiyol Bul; 2008 Jul; 42(3):509-14. PubMed ID: 18822897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.
    Gavaldà J; Len O; Miró JM; Muñoz P; Montejo M; Alarcón A; de la Torre-Cisneros J; Peña C; Martínez-Lacasa X; Sarria C; Bou G; Aguado JM; Navas E; Romeu J; Marco F; Torres C; Tornos P; Planes A; Falcó V; Almirante B; Pahissa A
    Ann Intern Med; 2007 Apr; 146(8):574-9. PubMed ID: 17438316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which trial do we need? Aminopenicillin-gentamicin versus aminopenicillin-ceftriaxone for Enterococcus faecalis endocarditis.
    Luque-Paz D; Cuervo G; Miró JM; Tattevin P
    Clin Microbiol Infect; 2023 Jun; 29(6):676-678. PubMed ID: 36889644
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcome of Enterococcus faecalis infective endocarditis according to the length of antibiotic therapy: Preliminary data from a cohort of 78 patients.
    Pericàs JM; Cervera C; Moreno A; Garcia-de-la-Mària C; Almela M; Falces C; Quintana E; Vidal B; Llopis J; Fuster D; Mestres CA; Marco F; Miró JM;
    PLoS One; 2018; 13(2):e0192387. PubMed ID: 29462176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enterococcal endocarditis revisited.
    Pericás JM; Zboromyrska Y; Cervera C; Castañeda X; Almela M; Garcia-de-la-Maria C; Mestres C; Falces C; Quintana E; Ninot S; Llopis J; Marco F; Moreno A; Miró JM
    Future Microbiol; 2015; 10(7):1215-40. PubMed ID: 26118390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential in vitro susceptibility to ampicillin/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates.
    Westbrook KJ; Chilambi GS; Stellfox ME; Nordstrom HR; Li Y; Iovleva A; Shah NH; Jones CE; Kline EG; Squires KM; Miller WR; Tran TT; Arias CA; Doi Y; Shields RK; Van Tyne D
    J Antimicrob Chemother; 2024 Apr; 79(4):801-809. PubMed ID: 38334390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis.
    Euba G; Lora-Tamayo J; Murillo O; Pedrero S; Cabo J; Verdaguer R; Ariza J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4305-10. PubMed ID: 19667290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials.
    Mirna M; Topf A; Schmutzler L; Hoppe UC; Lichtenauer M
    Clin Res Cardiol; 2022 Oct; 111(10):1077-1086. PubMed ID: 34751788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum.
    Gavaldà J; Cardona PJ; Almirante B; Capdevila JA; Laguarda M; Pou L; Crespo E; Pigrau C; Pahissa A
    Antimicrob Agents Chemother; 1996 Jan; 40(1):173-8. PubMed ID: 8787901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an
    Werth BJ; Shireman LM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo synergism of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis assessed in the Galleria mellonella infection model.
    Thieme L; Hartung A; Makarewicz O; Pletz MW
    J Antimicrob Chemother; 2020 Aug; 75(8):2173-2181. PubMed ID: 32357212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.